umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Synergistic killing of Glioblastoma Stem-like cells by Bortezomib and HDAC Inhibitors
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Vise andre og tillknytning
2012 (engelsk)Inngår i: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 32, nr 7 ; Special Issue, s. 2407-2413Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: The malignant brain tumour glioblastoma is a devastating disease that remains a therapeutic challenge. Materials and Methods: Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines and conventional glioblastoma cell lines. Cell survival, proliferation and death were analyzed by fluorometric microculture cytotoxicity assay (FMCA), propidium iodide labeling and flow cytometry, and cell cloning through limiting dilution and live-cell bright-field microscopy. Results: Bortezomib and the HDAC inhibitors showed synergistic cell killing at clinically relevant drug concentrations, while the conventional cell lines cultured in serum-containing medium were relatively resistant to the same treatments. Conclusion: These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs.

sted, utgiver, år, opplag, sider
International Institute of Anticancer Research, 2012. Vol. 32, nr 7 ; Special Issue, s. 2407-2413
Emneord [en]
Glioblastoma, stem cells, proteasome inhibitor, HDAC inhibitor, TB101, R11 stem cells, U251 MG, GL15 cells
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-57605ISI: 000306254300003OAI: oai:DiVA.org:umu-57605DiVA, id: diva2:543575
Tilgjengelig fra: 2012-08-08 Laget: 2012-08-08 Sist oppdatert: 2018-06-08bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Personposter BETA

Asklund, ThomasKvarnbrink, SamuelHolmlund, CamillaWibom, CarlBergenheim, TommyHenriksson, RogerHedman, Håkan

Søk i DiVA

Av forfatter/redaktør
Asklund, ThomasKvarnbrink, SamuelHolmlund, CamillaWibom, CarlBergenheim, TommyHenriksson, RogerHedman, Håkan
Av organisasjonen
I samme tidsskrift
Anticancer Research

Søk utenfor DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric

urn-nbn
Totalt: 269 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf